Humacyte Receives $1.475M Commitment Of Symvess Acellular Tissue Engineered Vessel For Facilitation Of Hospitals In Saudi Arabia

Humacyte, Inc. has secured a minimum purchase commitment of $1.475 million for its Symvess acellular tissue engineered vessel to support a clinical evaluation program in Saudi Arabian hospitals. The company is also in discussions to establish a joint venture for the commercialization of Symvess in the region. As part of the initiative, Humacyte will train medical professionals and has committed not to negotiate commercialization rights with other parties in Saudi Arabia until July 2, 2026.